Recent Updates
Recently added Catalysts
XOMA Positive Sentiment Score: 70/100

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

Key Takeaway: XOMA Royalty Corporation announced that Chief Investment Officer Brad Sitko will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The event highlights XOMA's role in supporting biotech companies by acquiring potential future economics from their therapeutic candidates. Attendees can access the presentation online, and a replay will be available for 90 days post-event. This opportunity is expected to enhance XOMA's visibility and potentially engage with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • XOMA is gaining visibility through a key industry conference.
  • The company's role as a biotech royalty aggregator supports innovation.
  • Presentation at a notable event may attract interest from investors.

Full Press Release Details

EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025.
Mr. Sitko’s presentation will take place on Wednesday, April 9, 2025, at 10:30 AM PT.  The presentation can be assessed by visiting https://bit.ly/4l7bz6m.
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

Frequently Asked Questions

When will Brad Sitko present at the conference?

Brad Sitko's presentation is scheduled for April 9, 2025, at 10:30 AM PT.

Where can I access XOMA's conference presentations?

XOMA's presentations are available on their investor relations section at www.xoma.com.

What is the role of XOMA Royalty Corporation?

XOMA Royalty Corporation is a biotech royalty aggregator that helps improve human health.

How does XOMA support biotechnology companies?

XOMA acquires future economics to provide non-dilutive funding for biotech companies.

How long will the presentation replay be available?

The replay of the presentation will be available for 90 days after the event.

Last updated: Apr 2, 2025